Celgene Signs an Exclusive Worldwide License Agreement with Skyhawk to Develop Therapies Modulating RNA Splicing

FDA to Refuse Celgene for Filling Ozanimod’s NDA for the Treatment of Relapsing Multiple Sclerosis


  • Skyhawk to receive $80M up front, milestones, and royalties on sales. Celgene to get exclusive WW option to license IPR for the number of Skyhawk’s candidates targeting multiple autoimmune disorder, oncology, and immuno-oncology targets. Post option exercising, Celgene will be responsible for further development and commercialization of products
  • In 2018, the companies collaborated to discover and develop therapies utilizing Skyhawk’s STAR technology platform for the treatment of autoimmune disorders, oncology, and immuno-oncology diseases
  • Skyhawk’s SkySTAR (Small molecule Therapeutics for Alternative splicing of RNA platform) allows identifying of druggable sites and unique chemical matter for correcting mRNA mis-splicing resulting in novel therapies

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Behance